We have established a good relationship with global and regional partners in project introduction and external cooperation.
In 2013, we licensed-in Troxacitabine from Yale University. In 2015, we licensed-in Clevudine, an anti-Hepatitis B drug, from Yale University the early development of which our founder was involved in. In 2019, we licensed-in the new anticancer drug Siroquine (JP001). HebaBiz Biotech is regarded internationally as an ideal partner to develop the Chinese market due to our strong product development capability and project experience.